Accelr8's Q2 Revenues Drop Sharply As Novartis Deal Ends

Mar 21, 2012

NEW YORK (GenomeWeb News) – Accelr8 reported last week that its fiscal second-quarter revenues plummeted to $8,328 from $313,568 a year ago as a result of the expiration of an agreement with Novartis.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Already have an account?
Login Now.

Breaking News

Genotyping, Fine Mapping Identifies Single-Variant Resolution Loci for IBD
Microbiome Health Firm DayTwo Raises $12M
Immunovia Opens US Subsidiary, CLIA Lab
Cardinal Health to Distribute GenePOC Instrument, Assays in US
SOL Group Acquires Majority Stake in Personal Genomics
OncoDNA, Zogen Enter Strategic Partnership in Mexico

The Scan

More Reproducible

Two new Reproducibility Project: Cancer Biology studies have largely reproduced the original findings, ScienceInsider reports.

To Catch the Swap

DNA fingerprinting could catch some sample mix-ups at pathology labs, the New York Times says.

Face of the Suspect

A Maryland police department has turned to DNA phenotyping to develop a suspect sketch, WJLA reports.

This Week in Cell

In Cell this week: DNA methylation and T cell exhaustion, longevity in C. elegans, and more.

Main menu